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Abstract 
Background: The prevalence of abdominal obesity among women in UAE is exceptionally high. However, its impact 
on cardiovascular health has not been adequately investigated. The aims of this study were to investigate: (1) cor‑
relations between inflammatory and oxidative biomarkers vs. anthropometric and metabolic measures; (2) rates of 
dyslipidemia, diabetes, and hypertension and (3) risks of cardiovascular disease.
Methods: One hundred ten “healthy” overweight/obese Emirati women attending nutrition counselling clinics were 
randomly recruited. All participants had completed questionnaire, physical examination and laboratory assessment.
Results: The participants’ mean ± SD of age, body mass‑index, waist circumference were 39 ± 9 years, 34 ± 6 kg/
m2 and 100 ± 13 cm respectively. Among the studied women 45 % met diagnostic criteria for metabolic syn‑
drome showing a positive correlation of hsCRP with BMI (p = 0.002), body fat (p = 0.002) and waist circumference 
(p = 0.018). There was positive correlation of IL‑6 with waist circumference (p = 0.019) and adiponectin with HDL 
(p = 0.007). Prevalence of HDL <1.3 mmol/L or triglycerides ≥1.7 mmol/L were 82 %, dysglycemia 31 %, and hyper‑
tension 27 and 37 % of women had either ‘high’ or ‘moderate’ calculated cardiovascular 10‑year risk score.
Conclusion: The levels of inflammatory and oxidative stress markers were highly prevalent among overweight/
obese Emirati women and this may predispose to increasing cardiovascular risks at relatively young age. Thus effective 
strategies to impact cardiovascular burden and conducting outcome studies assessing the increased risk of cardiovas‑
cular disease and addressing obesity prevention among women are urgently needed.
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Background
The rising trends of obesity and diabetes in United Arab 
Emirates (UAE) impose serious cardiovascular health 
concerns [1]. The rapidly growing socio-economic 
changes in the country have fashioned the dietary hab-
its and lifestyle and lead to epidemics of obesity, dys-
lipidemia, diabetes, hypertension, and other related 
risks of cardiovascular disease [2]. Unfortunately, the 
local cultural norms make women more vulnerable to 
these adverse events, especially since they are unequally 
encouraged to participate in sports and health-promot-
ing activities [3, 4]. In addition, awareness, screening, and 
management campaigns that gratify women’s need are 
rare in the region.
The term ‘central or abdominal obesity’ has recently 
emerged as a predictor of cardiovascular disease [5, 6]. 
This anthropometric variable is determined by measur-
ing the waist circumference, which correlates with vis-
ceral fat better than the body mass-index (BMI) [7]. The 
mechanism that links abdominal fat distribution to car-
diovascular disease, however, remains unclear despite 
available hypotheses [8]. Central obesity is a cardinal 
feature of the metabolic syndrome [9], which is defined 
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as a cluster of risks that include adiposity, hypertension, 
dyslipidemia, and diabetes [10].The syndrome is associ-
ated with increased oxidative stress, subclinical inflam-
mation, and altered fibrinolysis [11, 12]. Its prevalence in 
this region is exceptionally high [13–15]. However, cen-
tral obesity is not included in most cardiovascular disease 
risk assessments. The current algorithms are mainly pop-
ulation-based rather than personalized predictions. Risks 
of cardiovascular disease in the population can be esti-
mated by the “10 years Framingham score” [16] or “ten-
year risk for a first atherosclerotic cardiovascular disease 
event or the Lifetime risk for a first event” [17].
Excess body fat impairs hemodynamic function, dis-
turbs redox homeostasis, and provokes pro-inflam-
matory responses [18]. Increased cytokine production 
generates reactive oxygen and nitrogen species from the 
visceral and subcutaneous fat. Adverse events of this fat-
driven cardiometabolic risks include a gradual deteriora-
tion in cardiovascular health, which is commonly seen in 
patients who have metabolic syndrome. In addition, the 
central obesity-associated inflammatory cascade in meta-
bolic syndrome causes other serious systemic diseases, 
such as diabetes and atherosclerosis [19, 20]. In the study 
of Acute Coronary Syndrome Patients in the Middle East 
(6266 patients), the prevalence of low HDL was more 
common in females than in males [21].
This study aimed primarily at assessing cardiovascular 
health risks associated with obesity in women in UAE. Its 
main objective was to highlight urgent needs for prompt-




This cross-sectional study was approved by the Research 
Ethics Committee of Al Ain Medical District Human 
Research Ethics Committee. The study complied with the 
Declaration of Helsinki. They agreed with the informed 
consent form, written informed consent was obtained 
from all participants. The participants were overweight 
or obese women who attended the Ambulatory Health 
Service (AHS) dietician clinics in Al Ain city of Abu 
Dhabi Emirate for counselling on weight reduction. 
Recruitments were random (every third entry on the 
appointment list) and assessments were performed prior 
to any weight reduction intervention. The inclusion cri-
teria were women, previously known to be healthy and 
aged 18 y or older with BMI ≥25  kg/m2. The exclusion 
criteria were women receiving weight-reduction inter-
ventions, taking lipid lowering drugs, regular medica-
tions (e.g., β-blockers, α-blockers, digoxin, diuretics, 
aspirin, nitrates, or hormones), having active chronic 
illness (e.g., rheumatoid arthritis, hyperthyroidism, and 
inflammatory bowel disease), pregnancy, or unable to 
give informed consent. Of the 256 women recruited, 110 
(43 %) met the eligibility criteria and were enrolled in this 
cross-sectional (baseline assessment) study. All partici-
pants completed the study face-to-face questionnaire and 
had physical examination and laboratory assessment as 
shown in Table 1.
Waist circumference was measured with an un-
stretched tape midpoint between the bottom of the rib 
cage and the tip of the iliac crest. Weight and height 
were measured to the nearest 0.1 kg and 0.1 cm, respec-
tively in a standing position without shoes and in light 
clothing by a digital scale. Body fat and fat-free masses 
were measured using Tanita body composition analyzer 
(Tanita Corporation, Tokyo, Japan). Blood pressure was 
measured on the right arm at rest for ≥5  min. Three 
consecutive measures were obtained at 1-min intervals 
with a standard mercury sphygmomanometer with an 
appropriate cuff size. The average of last two readings 
was used.
Inflammatory and oxidative stress markers
25-Hydroxyvitamin D, fasting blood glucose, high-den-
sity lipoprotein-cholesterol (HDL), low-density lipo-
protein-cholesterol (LDL), and triglycerides (TG) were 
analyzed by COBAS INTEGRA 400 Plus/E411 (Roche 
Diagnostics Corp., Indianapolis, USA). The labora-
tory performed internal quality controls before running 
samples and participated in External Quality Assurance 
program through the College of American Pathologists 
Proficiency Testing. Serum high sensitivity C-reactive 
protein (hsCRP) was measured using Synchron Clini-
cal System (UniCel DxC-800) from Beckman Coulter 
Inc (Fullerton, CA, USA). Adiponectin (Human Total 
Adiponectin/Acrp30 Quantikine, DRP300), interleu-
kin-6 (Human IL-6 Quantikine HS, HS600B), and tumor 
necrosis factor-α (Human TNF-α Quantikine, DTA00C) 
were measuring by enzyme-linked immunosorbent assay 
following the manufacturing protocols.
Metabolic syndrome definition
Metabolic syndrome was considered in women with at 
least three of the five International Diabetes Federation 
diagnostic criteria: (1) waist circumference ≥80 cm (for 
Middle East, Mediterranean population); (2) triglyc-
erides ≥150  mg/dL (1.7  mmol/L); (3) HDL <50  mg/dL 
(1.3  mmol/L); (4) systolic blood pressure ≥130  mmHg 
or diastolic blood pressure ≥85 mmHg; (5) fasting blood 
glucose ≥100  mg/dL (≥5.6  mmol/L) [10, 19]. Framing-
ham score for 10-year risk of cardiovascular disease [22] 
and 10-year and lifetime risks of atherosclerotic cardio-
vascular disease (ASCVD) were determined as previously 
reported [23].
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Statistical analyses
The statistical analyses were performed using the SPSS 
software version 21.0 (SPSS Inc., Chicago, USA) and 
R-freeware version 3.1.1 on UNIX platform. Continu-
ous variables with normal distribution were expressed 
as mean  ±  SD. The Spearman correlation was used 
as a nonparametric measure of statistical dependence 
between two variables among women with and without 
metabolic syndrome. The criterion of statistical signifi-
cance was p < 0.05 (2-tailed).
Results
Patient characteristics
Demographic, anthropometric, and laboratory findings 
in all participants are shown in Table 1. Only 16 (15 %) 
women had a self-reported physical activity ≥150  min/
week. None of the participants reported history of hyper-
tension. Seven (6 %) women reported diabetes which was 
controlled on life style measures, 8 (7 %) on diet for dys-
lipidemia, 9 (8  %) polycystic ovary syndrome, and one 
(1 %) tobacco smoking.
Inflammatory and oxidative stress markers
Prevalence of hypertriglyceridemia was 10  %, low HDL 
80 %, hypertension 27 %, and elevated fasting blood glu-
cose more or equal to 5.6  mmol/L was 31  % (Table  2). 
Adiponectin negatively correlated with triglycerides 
Table 1 Characteristics of the studied women (n = 110)
LDL low-density lipoprotein, HDL high-density lipoprotein, hsCRP high sensitivity 
C-reactive protein, IL-6 interleukin-6, TNF-α tumor necrosis factor-alpha
Demographics and medical history [number (percentage) of patients]
 Age, mean ± SD, years 39 ± 9 (median 36, range 30–65)
 Education
  Primary 28 (25)
  Secondary 38 (35)
  University 44 (40)
 Marital status
  Married 81 (74)
  Single 18 (16)
  Divorced 11 (10)
 Occupation
  Housewife 72 (65)
  Employed 22 (20)
  History of dyslipidemia 8 (7)
  History of diabetes 7 (6)
  Polycystic ovary syndrome 9 (8)
  Self‑physical activity ≥150 min/
week
16 (15)
Anthropometrics, mean ± SD (median and range)
 Waist circumference (cm) 100 ± 13 (median 99, range 71–144)
 Hip circumference (cm) 116 ± 11 (median 116, range 
49–148)
 Waist: hip ratio 0.86 ± 0.08 (median 0.86, range 
0.63–1.11)
 Body mass index (kg/m2) 34 ± 6 (median 33, range 25–58)
 Weight (kg) 84 ± 14 (median 83, range 58–123)
 Systolic blood pressure (mmHg) 120 ± 13 (median 120, range 
92–158)
 Diastolic blood pressure (mmHg) 73 ± 9 (median 73, range 53–100)
 Percent body fat 41 ± 5 (median 41, range 29–54)
 Percent fat‑free muscle 47 ± 5 (median 46, range 36–64)
Laboratory biomarkers, mean ± SD (median and range)
 Fasting blood glucose (mmol/L) 5.5 ± 1.8 (median 5.1, range 
3.9–19.4)
 Hemoglobin A1c (%) 5.8 ± 0.9 (median 5.7, range 
4.5–12.0)
 Total cholesterol (mmol/L) 4.9 ± 0.9 (median 4.9, range 3.4–7.7)
 LDL cholesterol (mmol/L) 3.0 ± 0.7 (median 3.0, range 1.4–5.4)
 HDL cholesterol (mmol/L) 1.1 ± 0.3 (median 1.0, range 0.5–2.6)
 Triglyceride (mmol/L) 1.0 ± 0.4 (median 1.0, range 0.4–2.3)
 Adiponectin (µg/L) 6.5 ± 3.4 (median 5.4, range 
1.1–18.4)
 hsCRP (mg/L) 7.8 ± 7.7 (median 5.4, range 
0.2–51.3)
 IL‑6 (pg/mL) 2.7 ± 2.1 (median 2.0, range 
0.2–14.0)
 TNF‑α (ng/L) 0.014 ± 0.04 (median 0.013, range 
0.007–0.037)
 25‑Hydroxyvitamin D (nmol/L) 21.6 ± 15.1 (median 17.0, range 
5.0–91.0)
Table 2 Prevalence of ‘metabolic syndrome’ criteria in the 
studied women (n = 110)
Values are number (percentage) of patients




 (1) Waist circumference ≥80 cm 103 (94) 7 (6)
 (2) Triglycerides ≥1.7 mmol/L 11 (10) 99 (90)
 (3) HDL <1.3 mmol/L 88 (80) 22 (20)
 (4) Systolic blood pressure ≥130 mmHg 22 (20) 88 (80)
 (5) Diastolic blood pressure ≥85 mmHg 12 (11) 98 (89)
 (6) Fasting blood glucose ≥5.6 mmol/L 34 (31 %) 76 (69)
Combined criteria
 Dyslipidemia (criteria 2 or 3) 90 (82) 20 (18)
 Hypertension (criteria 4 or 5) 30 (27) 80 (73)
 Dyslipidemia + hypertension 25 (23) 85 (77)
 Dyslipidemia + diabetes 27 (25) 83 (75)
 Hypertension + diabetes 12 (11) 98 (89)
 Dyslipidemia + hypertension + diabetes 8 (7) 112 (93)
 Metabolic syndrome 49 (45)a 61 (55)
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(p  =  0.006), Table  3. HDL positively correlated with 
adiponectin (p  =  0.014) and negatively correlated with 
hsCRP (p = 0.012) and interleukin-6 (p = 0.017), Table 3. 
hsCRP positively correlated with BMI (p  =  0.001), 
waist circumference (p  =  0.000), hip circumference 
(p = 0.000), percent body fat (p = 0.007), free fat muscle 
(p =  0.028), and triglyceride level (p =  0.000). Consist-
ently, IL-6 positively correlated with waist circumfer-
ence (p = 0.010), hip circumference (p = 0.019), percent 
body fat (p  =  0.003), and free fat muscle (p  =  0.008). 
TNFα also positively correlated with percent body fat 
(p = 0.008), Table 3. Thus, the fat accumulation invoked 
significant inflammation.
Forty-nine women (45  %) met the International Dia-
betes Federation diagnostic criteria for metabolic syn-
drome. In these women, hsCRP positively correlated 
with BMI (p =  0.002), waist circumference (p =  0.018), 
hip circumference (p  =  0.005), systolic hypertension 
(p =  0.004), and percent body fat (p =  0.002), Table  3. 
IL-6 and TNFα continued to show positive correlations 
with percent body fat, with p-values of 0.012 and 0.040, 
respectively (Table 3).
In the 61 women (55 %) without metabolic syndrome, 
adiponectin positively correlated with HDL (p = 0.007); 
hsCRP positively correlated with waist circumference 
(p = 0.034), and triglyceride levels (p = 0.01). IL-6 posi-
tively correlated with waist circumference (p  =  0.019), 
Table  3. Seventeen (15  %) women scored ‘high’ and 24 
(22 %) women scored ‘moderate’ on either Framingham 
10-year risk or 10-year risk for first atherosclerotic car-
diovascular disease event (Table 4).
Discussion
The most important findings in this study are the highly 
prevalent metabolic syndrome and risks of cardiovascu-
lar disease among the studied obese women (Tables 2, 4). 
The excess body fat in these women is shown to provoke 
significant subclinical inflammation (Table  3). The level 
of adiponectin (an adipocyte-derived cytokine, which 
reduces free fatty acids and promotes lipid metabolism) 
is found in the current study to negatively correlate with 
triglyceride level (p  =  0.006), positively correlate with 
HDL (p = 0.007) in women who do not have metabolic 
syndrome, and negatively correlate with waist circumfer-
ence in women who have metabolic syndrome (Table 3). 
This cardioprotective hormone has been known to 
improve insulin sensitization and ameliorates inflamma-
tion and consequently atherogenic processes [24, 25]. 
Despite its important significance, the level of adiponec-
tin is not routinely used in clinical practice and is not yet 
included in assessing cardiovascular risks.
Low-grade lingering inflammation (e.g., increased lev-
els of TNF-α and IL-6) and protein and lipid oxidation 
are commonly reported in individuals who have obesity 
[26, 27]. These biochemical alternations accelerate car-
diovascular disease [28]. For example, the strong corre-
lation between hsCRP and central obesity shown in the 
current study (Table 3) is an independent risk factor for 
future myocardial infarction [28]. The elevated levels of 
oxidative stress markers are associated with increased 
hsCRP and are independent of obesity and insulin resist-
ance [29]. Thus, this laboratory determinant is warranted 
in screening and monitoring patients who have obesity. 
However, the clinical utility of other inflammatory bio-
markers, such as IL-6 and TNF-α requires further out-
come studies.
The majority of studied women were deficient of vita-
min D (Table 1). A potential link between vitamin D defi-
ciency and cardiovascular disease has been suggested in 
a cross-sectional study [30]. The data, however, are still 
insufficient to conclude that low levels of vitamin D inde-
pendently increase the cardiovascular risk.
Insulin resistance, inflammation, oxidative stress, 
and other metabolic disorders (e.g., hyperlipidemia) 
are related disturbances in women with metabolic syn-
drome [31]. Abdominal obesity is an important predic-
tor of dyslipidemia and T2DM [5–8]. BMI and waist 
circumference have been combined with triglycerides 
and HDL to determine visceral adiposity index, a gen-
der-specific indicator [32]. This determination has a 
J-shaped relationship with risks of cardiovascular dis-
ease as well as all-cause mortality. In the current study, 
increased waist circumference was found in 94 % of the 
studied women (Table 1), and it was significantly associ-
ated with increased cardio-metabolic and inflammatory 
biomarkers (Table  3). Reference values for waist cir-
cumference are expected to vary among different ethnic 
groups. The National Cholesterol Education Program 
(NCEP), World Health Organization (WHO), Inter-
national Diabetes Federation (IDF), and modified ver-
sion specific to the people of South Asian origin (ATP 
III SAS, 2009) may not represent cutoffs suitable for 
all regions in the world. Population-specific studies are 
needed to assess the impact of waist circumference on 
women’s health.
Enhanced systemic inflammation and oxidative stress 
are associated with elevated plasma triglyceride-rich 
lipoproteins and oxidized lipoprotein(a) phospholipids 
that underlie cardiovascular risks [33]. These biochemical 
disturbances are further augmented by the loss of anti-
inflammatory, anti-oxidative, and atheroprotective prop-
erties of HDL and its apolipoproteins. Low HDL is the 
second important determinant of metabolic syndrome 
after waist circumference (Table  2). Women who have 
obesity are more prone to dyslipidemia, mainly increased 
triglycerides, decreased HDL, and abnormal ratio of 
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triglycerides to HDL. Low HDL is a strong biomarker of 
cardiovascular disease, atherogenic dyslipidemia, pro-
inflammatory cytokines, and oxidative stress [21, 34]. In 
the study of Acute Coronary Syndrome Patients in the 
Middle East (6266 patients), the prevalence of low HDL 
was more common in females than in males [21]. Obesity 
is the main culprit for low HDL and optimizing women’s 
healthy lifestyles (e.g., moderate weight loss combined 
with exercise and smoking cessation) will significantly 
increase HDL [21].
Thus, comprehensive campaigns are urgently needed to 
improve female awareness of the serious adverse events 
of obesity. Moreover, national strategies are needed to 
facilitate women’s healthy lifestyles, such as parks, gym 
facilities in and out work places, in-door sport activities, 
and walking tracks in streets. Overcoming cultural barri-
ers to healthy dietary choices and physical activities are 
important factors in combating obesity in women.
Conclusions
Obesity among women is coupled with several cardio-
vascular risk factors, such as hypertension, dyslipidemia, 
diabetes, and subclinical inflammation. Metabolic syn-
drome is highly prevalent among the studied women 
who have obesity. Weight reduction and regular exercise 
are strongly recommended to all overweight women in 
order to prevent cardiovascular diseases. Outcome stud-
ies assessing the increased risk of cardiovascular disease 
among women who have obesity are urgently needed. 
Studies addressing obesity prevention are essential.
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